The estimated Net Worth of Ventures Fund V General Par... is at least $410 millier dollars as of 11 May 2018. Ventures Par owns over 281,250 units of Evelo Biosciences Inc stock worth over $410,252 and over the last 7 years Ventures sold EVLO stock worth over $0.
Ventures has made over 1 trades of the Evelo Biosciences Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Ventures bought 281,250 units of EVLO stock worth $4,500,000 on 11 May 2018.
The largest trade Ventures's ever made was buying 281,250 units of Evelo Biosciences Inc stock on 11 May 2018 worth over $4,500,000. On average, Ventures trades about 281,250 units every 0 days since 2018. As of 11 May 2018 Ventures still owns at least 18,233,403 units of Evelo Biosciences Inc stock.
You can see the complete history of Ventures Par stock trades at the bottom of the page.
Over the last 7 years, insiders at Evelo Biosciences Inc have traded over $41,656 worth of Evelo Biosciences Inc stock and bought 38,579,214 units worth $81,620,674 . The most active insiders traders include Ventures Fund Iv General Pa..., Noubar Afeyan et Ventures Fund Iv General Pa.... On average, Evelo Biosciences Inc executives and independent directors trade stock every 45 days with the average trade being worth of $19,676. The most recent stock trade was executed by Mark Bodmer on 7 November 2023, trading 6,625 units of EVLO stock currently worth $149.
evelo biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines – monoclonal microbials. monoclonal microbials are orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut. these new medicines are broadly applicable across many diseases – including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases and cancer. monoclonal microbials have the potential to fundamentally change traditional models of drug discovery and development. by finding and selecting naturally occurring monoclonal microbials with defined therapeutic effects, evelo can improve the speed, cost and success of drug discovery and development. evelo’s platform enables pharmacological intervention at all stages of disease with naturally occurring, safe and effective monoclonal microbials. evelo biosciences was conceived and created within venturelabs®, flag
Evelo Biosciences Inc executives and other stock owners filed with the SEC include: